I nfluenza B viruses (IBVs) co-circulate in humans as two lineages based on the genetic and antigenic differences of the haemagglutinin (HA) glycoprotein. The two lineages-Yamagata (named after the B/Yamagata/16/88 strain) and Victoria (named after the B/Victoria/2/87 strain)-are thought to have diverged from a common ancestor strain in the 1970s 1, 2 . Although IBVs are responsible for 20-30% of influenza cases per year on average, IBV is the predominant cause of influenza disease in some years [3] [4] [5] [6] . Current studies challenge the notion that influenza B cases are clinically milder than those of influenza A, with the finding of no difference between influenza B and influenza A in terms of the length of hospital stay, intensive care unit admission frequency, or rate of death among hospitalized influenza patients 7 . Additionally, epidemiological data suggest that IBVs disproportionally afflict children. During the 2010-2011 influenza season in the USA, IBVs accounted for 25% of all influenza infections but caused 38% of influenza-related paediatric deaths, and nearly half of these children had no pre-existing health conditions 8 .
Neuraminidase (NA) inhibitors are the only antivirals officially recommended by the Advisory Committee on Immunization Practices (ACIP) for the treatment of influenza virus infection 9 . This is particularly problematic for IBV infections, because oseltamivir has been shown to be less effective when treating influenza B than when treating influenza A in both paediatric and adult outpatient populations [10] [11] [12] . Furthermore, zanamavir (an alternative NA inhibitor) is not approved for children under the age of seven 9 . Given the substantial disease burden attributable to IBV despite the availability of vaccines and antivirals, the development of therapeutics, such as the monoclonal antibodies (mAbs) presented here, is crucial.
There have been reports of murine and human mAbs against the IBV HA [13] [14] [15] , but no broadly cross-reactive, protective mAbs binding the IBV NA have been reported thus far. The potential of the IBV NA globular head domain to harbour highly conserved epitopes has been recognized for some time 16 . mAbs against the IBV NA were previously isolated, yet the antibodies were not assessed for in vivo protection, and the structures of the antibody bound to NA were not solved [16] [17] [18] . Although the importance of anti-NA immunity in protection from viral infection has been extensively demonstrated [19] [20] [21] [22] [23] [24] [25] [26] [27] [28] , far less is known about NA epitopes compared to HA epitopes. Although NA does not serve as the receptor binding protein, it is critically responsible for freeing nascent virus from host cells and virus in the airway from mucins [29] [30] [31] , so antibodies that bind to the NA and interfere with its activity may confer protection through several mechanisms. Here, for the first time, we extensively characterize a panel of broadly cross-reactive mouse mAbs against the IBV NA in vitro and in vivo. We also present structures of recombinant IBV NA in complex with the fragment antigen-binding (Fab) portion of the antibody, allowing for a direct comparison of structural binding footprints with critical binding residues (mapped using escape mutagenesis). Furthermore, such studies highlight the potential benefits of targeting the conserved regions of the NA when designing innovative influenza virus vaccines. 
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with various degrees of mutations as compared to the germline sequences (Supplementary Data Set 1). All five mAbs displayed broad cross-reactivity to purified whole virus and rNA in enzymelinked immunosorbent assays (ELISAs) and functionally inhibited NA enzymatic activity in enzyme-linked lectin assays (ELLAs) ( Fig. 1a,b ). Most mAbs displayed minimal binding concentrations to rNA in the sub-micromolar range, with binding to certain rNA substrates reaching minimal binding concentrations in the nanomolar range (1.5-150 nM). These findings were corroborated by affinity measurements via biolayer interferometry where all but one mAb (4B2) reached sub-nanomolar binding affinities ( Supplementary Fig. 1 ). However, for some mAb/NA combinations binding was only observed at higher antibody concentrations (> 10 ug/ml). Because whole virus was coated based on amount of total protein in the preparation, the minimal binding concentrations in these ELISAs tended to be greater, on average, than those in which rNA was used as a substrate; other differences in binding between whole virus and rNA may be attributed to variation in protein folding and epitope availability. As expected, if a mAb did not bind the NA from a particular strain at a concentration of 10 ug/ml, it did not display NI activity against that strain. Binding and NI activity against the ancestral B/Lee/40 strain was weak, but still present, compared to the negative control. By displaying a subsample of IBV NA amino-acid sequences as a phylogenetic tree, we observe that the strains used in this study are representative of the aminoacid sequence diversity of IBV NAs, strengthening the conclusion that these anti-NA mAbs are broadly cross-reactive ( Fig. 1c ). Protective epitopes on the IBV NA have yet to be described. To map the relevant epitopes on the surface of the NA protein, we carried out electron microscopic analysis of the complex between rNA and the Fab portions of antibodies 1F2 and 4F11. We focused our analysis on 4F11 (because it displayed the widest binding breadth and greatest binding affinities overall) and 1F2 (because it displayed the strongest binding affinity to the ancestral B/Lee/40 strain) Fab fragments. The resulting density maps (resolution of ~25 Å) were interpreted ( Fig. 2a ,b) using coordinates from the X-ray structures of NA from B/Brisbane/60/2008 (PDB ID: 4CPL) and a Fab that binds an IBV HA (PDB ID: 4FQL). Oblique and top views of the complex ( Fig. 2a,b ) enable visualization of the locations of the bound antibodies at the periphery of the NA tetramer, indicating that 1F2 has an orientation that is tilted relative to the plane of the NA tetramer, while 4F11 binds in an orientation in which the Fab is in the same plane as that of the tetramer. In Fig. 2c , the top view of antibody binding is shown with respect to the NA enzymatic active site. Detailed inspection of the footprints of the bound Fab molecules shows that the structural footprints of 4F11 and 1F2 are adjacent to each other, but separate (Fig. 2d ). The amino-acid residues of the binding footprints are highly conserved across all IBVs, consistent with the broad binding profiles of mAbs 4F11 and 1F2 ( Fig. 2e ). Interestingly, the binding sites of both Fabs appear not to directly overlap the enzymatic active site of NA ( Fig. 2c ). Our reconstructions thus show that antibodies that inhibit NA activity need not contact the catalytic site directly and instead may function by binding and sterically hindering access of the NA to the substrate.
Residues critical for antibody binding were identified through the generation of escape mutant IBVs. Escape mutants generated against four of the five mAbs showed drastic loss of binding to mAbs via immunofluorescence staining of infected Madin-Darby canine kidney (MDCK) cells ( Supplementary Fig. 2a,b) . Interestingly, the 4B2 escape mutant retained robust binding to the antibody, but is nevertheless a true escape mutant, as demonstrated by its ability to grow to high titres compared to wild-type (wt) virus in the presence of antibody ( Supplementary Fig. 2c ). In this instance, mutations in other gene segments may have contributed to the ability of the mutant virus to escape antibody pressure. The critical residues identified in 1F2 and 4F11 escape mutants (E338K and G385R, respectively) are located either within or at the periphery of the binding footprints determined by electron microscopy ( Supplementary Fig. 2d ). The critical residue identified in the 3G1 escape mutant (G346R) maps to a location close to the active site, consistent with the finding that this was the only one of the analysed mAbs that could inhibit NA enzymatic activity to levels comparable to oseltamivir when using a small-molecule substrate ( Supplementary Fig. 3f ). Interestingly, mAb 1F2, which has a footprint adjacent to the 3G1 escape mutation, competed with mAb 3G1 in an ELISA assay ( Supplementary  Fig. 4 ). This was an asymmetric interaction because mAb 3G1 was unable to block 1F2 binding. The critical residue identified in the 1F4 escape mutant (Q453R) mapped close to the monomer-monomer interface of the NA tetramer. Of relevance, a quaternary, protective epitope spanning two monomers of the NA from pandemic H1N1 (A/California/07/2009) has been previously reported as the target of a human mAb 32 . It is conceivable that 1F4 binds to IBV NA in a similar manner. mAb 1F4 asymmetrically competed with mAb 4F11, The top view also highlights the location of the active site and framework residues (blue and orange, respectively). In the oblique view, the 1F2 and 4F11 binding footprints (green and magenta, respectively) are highlighted on the surface of the NA tetramer, with the corresponding Fab coordinates displaced away from the highlighted epitope region for purposes of visualization (grey arrow, d). e, Binding footprints of both Fabs shown on a single NA tetramer to highlight their non-overlapping, but spatially adjacent locations. Residues within the binding footprint are coloured as a heatmap based on per cent amino-acid conservation (red, 98-100% conserved; orange, 75-98% conserved; yellow, 50-75% conserved).
suggesting that it binds closer to the 4F11 footprint than to the 1F2 footprint ( Supplementary Figs. 2 and 4 ). Finally, deep sequencing of the 4B2 escape mutant did indeed reveal a non-synonymous mutation in NA (G344E), although the mutation does not strongly alter the binding of mAb 4B2 as assessed by immunofluorescence ( Supplementary Fig. 2d ). Competition ELISA analysis corroborated these findings with asymmetric competition between 4B2 with both 1F2 and 4F11 ( Supplementary Fig. 4 ). The mutation found in the 4B2 escape mutant is located right above both the 1F2 and the 4F11 footprint. All generated escape mutants lost sensitivity to the respective mAbs in an NI assay with the exception of the 4B2 escape mutant, which was still inhibited by mAb 4B2 ( Supplementary Fig. 6 ). However, this virus does not seem to escape by abolishing antibody binding to the NA, as discussed above ( Supplementary Fig. 2c ).
As previous reports have demonstrated the potential of influenza A virus NA-directed antibodies to protect in vivo 25, 27 , we decided to test the in vivo efficacy of our panel of mAbs in a wellestablished influenza virus challenge model, using female BALB/c mice. For all five mAbs, mice were fully protected from morbidity ( Supplementary Fig. 5a ,d) and mortality ( Fig. 3a,d ) when administered antibody prophylactically at the highest tested dose (5 mg kg -1 ) and challenged with five murine lethal doses (mLD 50 ) of either B/Malaysia/2506/04 (Victoria lineage) or B/Florida/04/06 (Yamagata lineage) virus strains. At lower prophylactic doses of 1 mg kg -1 and 0.5 mg kg -1 , the mAbs did not prevent morbidity ( Supplementary Fig. 5b ,c), but nevertheless prevented mortality against B/Malaysia/2506/04 virus, with 1F2 demonstrating 100% protection at both of the lower doses tested (Fig. 3b ,c). All five mAbs were 100% protective when administered to mice 24 h post infection (h.p.i.) with 5 mLD 50 B/Malaysia/2506/04 virus, and three of five were 100% protective when administered 48 h.p.i. (Fig. 3e,f and Supplementary Fig. 5e ,f).
To investigate the in vivo protective breadth of the mAb panel, mice were prophylactically administered with antibodies as in Fig. 3 , but were killed on days 3 or 6 for lung titre analysis. When mice were challenged with B/Malaysia/2506/04 virus, lung titres were significantly reduced on day 6, but not day 3, post infection relative to the negative control group (P ≤ 0.0001), suggesting enhanced viral clearance as a possible mechanism of protection ( Fig. 4a ). A similar pattern was also seen when mice were challenged with 
B/Yamagata/16/88, B/Victoria/2/87 and B/Lee/40 viruses, respectively ( Supplementary Fig. 3a -c). NA antibodies, which are typically considered non-neutralizing, have been shown to decrease plaque size, but not plaque number, in plaque reduction neutralization assays (PRNAs), an in vitro phenomenon that stems from their ability to inhibit viral egress 25, 27, 29, [32] [33] [34] . Our anti-NA mAbs displayed this phenotype in a PRNA when tested against B/Malaysia/2506/04 virus (Fig. 4b,c ). Additionally, recent findings have shown that Fc-Fcγ receptor interactions are necessary for broadly reactive HA head-, HA stalk-and NA-directed antibodies to mediate protection in vivo [35] [36] [37] . In light of the increasingly recognized implications of Fc receptor-mediated effector functions, such as antibody-dependent cell-mediated cytotoxicity (ADCC) and antibody-dependent cellular phagocytosis (ADCP), we decided to test the ability of our IBV NA-directed mAbs to engage with and activate Fc receptors in vitro. Using a commercially available ADCC Reporter Assay Core Kit (Promega), which uses Jurkat cells engineered to express firefly luciferase upon Fc receptor activation, we confirmed that all five mAbs displayed ADCC activity when incubated with MDCK cells infected with B/ Malaysia/2506/04 or B/Florida/04/06 virus, respectively ( Fig. 4d and Supplementary Fig. 3d,e ). Four of the five mAbs displayed ADCC activity when incubated with cells infected with B/Yamagata/16/88 virus, with the exception of 3G1, which is expected because 3G1 does not bind the NA of B/Yamagata/16/88 at low concentrations.
As mentioned, 3G1 was the only mAb that possessed a critical binding residue located directly adjacent to the enzymatic active site ( Supplementary Fig. 2d ). Yet, all mAbs displayed robust NI activity by ELLA, an assay that uses fetuin as a substrate (Fig. 1c ). The ability of antibodies that bind epitopes outside of the active site to inhibit NA enzymatic activity by ELLA has been documented in the case of N1-and N2-binding mAbs 25, [38] [39] [40] . Fetuin, a glycoprotein (molecular weight of 48.4 kDa), is immobilized to the 96-well plate during the ELLA coating process, so it is conceivable that antibodies that bind distal to the active site may inhibit access of the NA to fetuin by steric hindrance. To understand if this may account for the mechanism of inhibition in some of the other antibodies we studied, we assessed NI activity in an NA-Star assay, which uses a small, soluble chemiluminescent substrate (molecular weight of 684.5 Da). All five mAbs inhibited NA activity in the NA-Star assay to some extent, but only 3G1 was able to achieve 100% inhibition with a half-maximum inhibitory concentration (IC 50 ) comparable to that of oseltamivir, a small-molecule NA inhibitor (molecular weight of 312.4 Da) ( Supplementary Fig. 3f ). These data also support the hypothesis that the epitope of 3G1 overlaps-or is in immediate proximity to-the enzymatic active site. In separate studies, we tested the role of steric hindrance by removal of the Fc region of the antibodies. Inhibition studies showed that 4F11 Fab, but not 1F2 Fab, lost NI activity in the NA-Star assay, suggesting that steric hindrance plays a role in the NI of this antibody.
Importantly, influenza viruses may develop resistance to oseltamivir and other NA inhibitors. As most of the mAbs from this study probably bind distal to the NA active site, it was hypothesized that they could still effectively inhibit the enzymatic activity of drugresistant IBV strains. Indeed, when tested against an IBV strain (B/ Perth/211/2001) containing a known oseltamivir-resistance mutation (D197E) all five mAbs-even 3G1-inhibited NA activity (Fig. 4e ).
Finally, we compared treatment with mAb to treatment with oseltamivir in the mouse model. In the BALB/c mouse challenge model, a 20 mg kg -1 , twice-daily, 6-day-long oral regimen of oseltamivir initiated 48 h.p.i. with 5 mLD 50 B/Malaysia/2506/04 resulted in 100% survival ( Supplementary Fig. 7 ). However, timing of the onset of antiviral therapy with NA inhibitors is crucial, as the greatest reduction in morbidity has been observed when treatment is initiated 48 h before symptom onset in both paediatric and adult cases of uncomplicated influenza 9,41,42 . We thus chose to compare the therapeutic efficacy of mAb 1F2 to that of oseltamivir as late as 72 h.p.i. When administered at this time point, a single bolus of 1F2 (5 mg kg -1 ) delivered intraperitoneally (i.p.) performed superiorly to the twice-daily regimen of oseltamivir, initiated at the same time point (72 h.p.i.) and continued for six days (or until the mice succumbed to infection). Although not statistically significant, 60% of mice treated with mAb 1F2 survived, compared to 0% in the oseltamivir treatment group (Fig. 4g ). Corresponding weight loss curves are shown in Supplementary Fig. 3g .
Discussion
Here, for the first time, we have elucidated broadly reactive epitopes located on the influenza B virus NA, using both structural and escape mutant mapping of murine monoclonal antibodies. The antibodies we generated bound to both Victoria and Yamagata lineage IBVs spanning 73 years of antigenic drift. NA antibodies may inhibit enzymatic activity by binding, but they also possess Fc regions capable of binding to-and activating-effector cells. Indeed, we demonstrated the ability of our mAbs to robustly activate effector cells in vitro.
The critical importance of Fc effector functions such as ADCP and ADCC to the mechanism of protection of non-neutralizing antibodies against the influenza virus is becoming increasingly appreciated. It has been shown using Fc receptor knockout mice and mAbs deficient in Fc receptor binding (DA265-mutant Fc), for instance, that the protection mediated by broadly reactive HA-stalk antibodies in vivo is dependent on Fc-Fc receptor interactions 35, 36 . Furthermore, Leon et al. demonstrated that the Fc activation mediated by HA-directed mAbs is epitope-dependent 43 . Whether or not the NA mAbs described in this study depend on Fc receptor activation to mediate protection or whether or not the ADCC activation by NA-binding mAbs is epitope-dependent remains unknown, but may be elucidated using similar approaches. Of note, a human NA antibody activated ADCC to a lesser extent than an HA-stalk antibody in A549 cells infected with H3N2 influenza virus. However, when titrated into the assay, the NA-binding mAb was able to increase the level of ADCC achieved by the stalk-binding mAb in an additive fashion 44 . This finding implies that NA antibodies may be able to cooperatively enhance the levels of effector functions achieved by HA antibodies during natural infection, most probably by providing increased contact points for Fc-Fc receptor engagement on the surface of virus or infected cells.
Finally, we demonstrated that mAb 1F2 exhibited superior efficacy to the standard of care, oseltamivir treatment, when administered 72 h.p.i. in a mouse challenge model. Conceivably, the combined ability of an anti-NA antibody to interfere with NA enzymatic activity while engaging in effector functions that allow for enhanced, immune-mediated viral clearance may explain why mAb treatment is able to outperform treatment with NA inhibitor in vivo.
The mAbs in this study possess the potential to be developed into therapeutics for high-risk patient populations or against drugresistant strains of IBV, highlighting the benefits of targeting broadly protective NA epitopes in innovative influenza virus vaccine formulations. As the HA and NA drift independently, vaccines that elicit robust NA titres may prove especially useful in influenza seasons in which an HA drift event occurs.
Methods
Cells, viruses and proteins. As described previously 27 , MDCK cells (originated from MDCK (NBL-2), ATCC CCL-34) were grown in complete Dulbecco's modified Eagle medium (DMEM, Life Technologies) supplemented with antibiotics (100 U ml -1 penicillin, 100 μ g ml -1 streptomycin [Pen-Strep], Gibco), 10% fetal bovine serum (FBS, HyClone) and 10 ml of 1 M HEPES (Life Technologies). Sf9 insect cells (originated from ATCC CRL-1711) were grown in TNM-FH insect medium (Gemini Bioproducts) supplemented with antibiotics (Pen-Strep) and 10% FBS and High Five cells (BTI-TN-5B1-4 subclone, Vienna Institute of Biotechnology) 45 were grown in serum-free SFX-insect cell medium NAturE MIcroBIology (HyClone) . SP2/0 mouse myeloma cells (originated from SP2/0-Ag14, ATCC CRL-1581) were passaged and maintained in complete DMEM supplemented with antibiotics (Pen-Step) before fusion with primary mouse splenocytes. Monoclonal, immortalized B cells (obtained from the hybridoma fusion) were initially grown in Clonacell-HY Medium E (Stemcell Technologies) and gradually switched to serum-free hybridoma medium (Hybridoma-SFM, Life Technologies) for high-volume production. All cell lines used tested negative for mycoplasma contamination using the MycoAlert Mycoplasma Detection Kit (Lonza). No cell lines were further authenticated in this study.
The The recombinant proteins used (B/Yamagata/16/88, B/Malaysia/2506/04, B/Florida/04/06, B/Brisbane/60/08 and B/Wisconsin/1/10 NAs) were expressed in High Five cells and purified from cell culture supernatants as described previously 46, 47 . In brief, cultures were infected with recombinant baculoviruses at a multiplicity of infection (MOI) of 10. Supernatants were then collected by low-speed centrifugation at ~72 h post infection and purified by using Ni-nitrilotriacetic acid resin (Qiagen) according to a published protocol 47 .
Generation and screening of mAbs. Similar to the protocol described previously 27, 48 Three days post-boost, this one mouse was killed and its spleen was removed in a sterile manner. The spleen was flushed forcefully with serum-free DMEM (with antibiotics (Pen-Strep)) using a 10 ml syringe with a 20-gauge needle, followed by repeated mashing with flat-ending forceps. Splenocytes and SP2/0 myeloma cells (in log phase) were combined in a 5:1 ratio and cell fusion was mediated via slow, dropwise addition of 1 ml polyethylene glycol (molecular weight of 4,000 g/mol). The splenocyte/SP2 mixture was resuspended in 25 ml of complete DMEM (supplemented with antibiotics (Pen-Strep), FBS and HEPES) and left to incubate for 24 h. After incubation, the cells were spun down, resuspended in 10 ml of complete DMEM, mixed with a proprietary bottle of 90 ml of semisolid Clonacell-HY Medium D (Stemcell Technologies) and dispensed onto tissue culture dishes (10 ml each) using a 10 ml syringe with a 15-gauge Luer Stub adapter (Becton Dickinson). Individual colonies were picked 10 days later and transferred into 96-well plates containing Clonacell-HY Medium E. Five days after transfer to 96-well plates, hybridoma supernatants were screened by ELISA for binding reactivity to B/Lee/40 (purified, whole virus), B/Yamagata/16/88 (rNA) and NI activity to B/Wisconsin/1/2010 virus. Positive clones were isotyped using a Pierce rapid antibody isotyping kit (Life Technologies), and only the mAbs isotyped to the IgG heavy-chain subclasses were selected for further expansion and purification. All animal procedures were performed in accordance with the Icahn School of Medicine at Mount Sinai Institutional Animal Care and Use Committee (IACUC).
Expansion and purification of mAbs. mAbs were produced and purified as described previously 27 . Fab fragments for mAbs 1F2 and 4F11 were generated by papain digestion (by Southern Biotech).
ELISA. ELISAs were performed as described previously 27 . An endpoint titre was defined as the final concentration at which the antibody signal remained greater than three standard deviations above the average of the blank wells, as described in ref. 49 .
ELLA. ELLAs, used to determine NA inhibition (NI) activity, were performed as described in detail in previous reports 26, 27 .
Sequencing variable sequences of B NA antibodies.
A total of 5 × 10 6 cells from hybridoma cell lines were used to purify the total mRNA using a Direct-zol RNA Miniprep kit (Zymo Research) according to the manufacturer's instructions. Purified RNA was reverse-transcribed using SuperScript III Reverse Transcriptase (Thermo Fisher) and the cDNA was stabilized in a terminal deoxynucleotidyl transferase (TdT) tailing reaction (Invitrogen). The product of TdT tailing was used as a template in a PCR reaction using high-fidelity Taq Platinum polymerase (Invitrogen) with a variable-region specific 5′ consensus anchor primer (5′ -GGCCACGCGTCGACTAGTACGGGIIGGGIIGGGIIG-3′ ) and a constantregion specific reverse primer (5′ -CCTTGACCAGGCATCCTAGAGTC-3′ or 5′ -GGAGGTGTGCACACTGCTGGACAG-3′ , for IgG2a and IgG2b, respectively). PCR reaction products were sequenced and the obtained sequences were entered into the IMGT/V-QUEST database tool (http://www.imgt.org/IMGT_vquest/ share/textes/) to determine the complete variable-region sequence as well as individual germline genes. In cases where the quality of the sequencing read was not sufficient, the PCR product was first cloned into Strataclone vectors (Agilent Technologies), which were then amplified in StrataClone competent cells, purified using a QIAPrep Spin Miniprep Kit (Qiagen) and then sequenced before entering them into the IMGT/V-Quest.
Antibody/antigen biotinylation. Antibodies and rNA were biotinylated using an EZ-Link NHS-PEG 4 -Biotin kit (Thermo Fisher Scientific) according to the manufacturer's instructions. K D determination using biolayer interferometry. Antibody dissociation constants (K D values) were determined by biolayer interferometry using an Octet Red96 instrument (ForteBio), as described previously 37 . Biosensors were loaded with rNA from B/Malaysia/2506/04.
Phylogenetic tree generation.
A subsample of 280 IBV NA amino acid sequences were chosen to form the phylogenic tree. For years in which 10 or fewer sequences were available, all sequences were used, and for years with more than 10 sequences, 10 sequences were randomly chosen to minimize the bias of more recent isolates. Sequences were aligned using MUSCLE and manually edited using the MEGA 6.0 software when applicable. A phylogenetic tree was assembled using the Clustal Omega web server with a neighbour-joining clustering method and default settings. The tree was cleaned and edited using FigTree.
Negative-stain electron microscopy. Recombinant NA and Fabs were diluted with buffer (5 mM HEPES, 150 mM NaCl pH 7.3) to ~0.02 mg ml -1 and 0.04 mg ml -1 , respectively. To prepare Fab bound samples, equal volumes of NA and Fabs 1F2 or 4F11 were mixed and incubated for 5-10 min. The samples were adsorbed to plasma-cleaned (Solarus Model 950 cleaner, Gatan) electron microsope grids coated with continuous carbon film, which were subsequently washed with buffer and stained with 0.75% uranyl formate. Images were collected using EPU software (FEI) on a Tecnai T12 electron microscope (FEI) fitted with a 4K charge-coupled device camera (Gatan) at an effective pixel size of 0.18 nm in the specimen plane. The software package RELION 1.4 (ref. 50 ) was used to obtain three-dimensional reconstructions. The maps for unbound NA and for the complexes with 1F2, and 4F11 were constructed using 47,592, 4,326 and 13,665 particles, respectively, and visualized using UCSF Chimera software 51 .
Modelling Fab binding footprints. NA and Fab (Influenza B HA Fab CR8033) X-ray coordinates (PDB IDs: 4CPL and 4FQL, respectively) were fitted to density maps using UCSF Chimera software. To highlight the binding footprints of the Fabs, the regions of NA that most closely interacted with each Fab were identified by manual inspection.
Multiple sequence alignment. Sequences were obtained from the Global Initiative on Sharing All Influenza Data (GISAID, http://platform.gisaid.org/), with any laboratory-associated strains or truncated sequences removed from analysis. There were a total of 2,409 sequences in the final file used for alignments. Sequence alignments were performed using MEGA 6.0 software (MUSCLE alignment).
Per cent conservation calculation. Escape residues were isolated from the whole NA protein sequence alignment using sequence editing tools in MEGA 6.06. A subsample of 944 sequences was used for calculations. For years in which 50 or fewer sequences were available, all sequences were used, and for years with more than 50 sequences, a random selection of 50 sequences was chosen to minimize the bias of more recent isolates. To obtain the percentage of sequences that contained a specific amino acid at each escape residue location, the amino-acid phenotypes at the site were sorted and then divided by the total number of sequences.
Generation of IBV anti-NA mAb escape mutant viruses. mAb escape mutant variants of B/Malaysia/2506/04 virus were generated based on the methods described in ref. 25 . mAb (250 μ g) and virus (10 6 p.f.u.) were combined (total NAturE MIcroBIology volume, 800 μ l), incubated for 1 h at room temperature (RT), split evenly into thirds and injected into three 8-day-old embryonated chicken eggs. After incubating for 72 h at 33 °C, allantoic fluid was collected and plaqued in the presence of mAb (100 μ g ml -1 in both inoculum and overlay). After incubating for 72 h at 33 °C, plaque assays were inspected for escape variants (evidenced by large plaque size). Large plaques were picked and inoculated into 10-day-old embryonated chicken eggs for amplification. All escape mutant variants, excluding that of mAb 4B2, were generated in this way. MAb 4B2 did not produce a viral escape mutant when using this technique and therefore a second technique, which is usually applied for more difficult target epitopes, was applied as follows. For generating escape mutants of 4B2, B/Malaysia/2506/04 virus was serially passaged on an MDCK cell monolayer in the presence of increasing amounts of mAb, with a starting concentration of 0.25 × IC 50 (as calculated from the NI assay against B/Malaysia/2506/04 virus). Initially, MDCK cells in one well of a six-well plate were infected with B/ Malaysia/2506/04 virus at an MOI of 0.1 in the presence of 0.5 × IC 50 of mAb. After incubating for 72 h at 33 °C, 10 μ l of supernatant was collected and used to directly inoculate a fresh monolayer of MDCK cells in the presence of increased mAb concentration. This process was repeated for 15 passages, until the final antibody concentration was ~1 mg ml -1 . Throughout serial passaging, successful infection was confirmed by the presence of the cytopathic effect (CPE) or, if CPE was not clear, positive staining with polyclonal anti-IBV mouse serum (the detailed immunostaining procedure is described in the section 'Evaluation of prophylactic and therapeutic efficacy in mice'). Both CPE and positive immunostaining were present in the last passage. Virus was also passaged in the presence of an irrelevant mouse mAb (3C12, anti-N8, IgG, characterized previously in ref. 27 ) throughout all experiments to control for mutational variants obtained from passaging alone. Viruses were plaque purified once serial passaging was completed to create monoclonal stocks for deep sequencing and growth curve analysis.
Deep sequencing of escape mutant variants. RNA from the escape mutant variants was obtained using a Direct-zol RNA kit (Zymo Research). Samples were processed using the Illumina TruSeq RNA Sample Preparation Kit according to the manufacturer's instructions and sequenced using a MiSeq Illumina instrument. Reads were consolidated and aligned to B/Malaysia/2506/04 using Bowtie2. The assembled genomes and minority variants were visualized with the Integrative Genomic Viewer (IGV) (Broad Institute).
Immunofluorescence. To screen for escape mutants, MDCK cells were plated in 96-well, sterile, flat-bottom tissue culture plates (Sigma) and subsequently infected with either wt B/Malaysia/2506/04 or mutant viruses at an MOI of 10. After incubation for 18 h at 33 °C in MEM lacking TPCK-trypsin (to limit viral growth to one infectious cycle), medium was removed and cells were fixed with 3.7% formaldehyde for at least 1 h at 4 °C. The formaldehyde was discarded and the cell monolayer was blocked with 3% milk in PBS for at least 1 h. For the primary antibody step, plates were incubated with either the respective IBV anti-NA mAb (30 °Cμ g ml -1 ), a positive infection control (a polyclonal cocktail of purified mouse mAb IgGs against the IBV HA (1:1,000 dilution), or irrelevant negative control mouse mAb 8H9 in PBS, 1% milk (100 μ l per well) for 1 h at RT, while shaking. Plates were washed three times with PBS and incubated with Alexa Fluor 488 goat anti-mouse secondary antibody in PBS, 1% milk (100 μ l per well) for 1 h at RT in the dark. Finally, after washing three additional times, cells were visualized via fluorescent microscopy.
Growth curve analysis.
To compare viral fitness in the presence of mAbs, growth curves were performed in MDCK cells. Cells were plated as a confluent monolayer in 12-well tissue culture plates (Sigma) and infected with virus at an MOI of 0.01 (final volume of 1 ml per well). The experiment was performed in triplicate for each time point and each antibody condition. mAb was added to the infection medium at a concentration of 10 μ g ml -1 . Cells were incubated at 33 °C and supernatant was collected at 12, 24, 48, or 72 h.p.i. The collected supernatant was clarified by centrifugation (at a relative centrifugal force of 3,000g for 10 min at 4 °C) and immediately stored at − 80 °C. For simplicity, only titres at 72 h.p.i. are reported here. Viral titres were assessed via haemagglutination assays, as described previously [52] [53] [54] .
Three-dimensional mapping of escape mutations. Escape mutations were represented on a three-dimensional structure of the NA of B/Brisbane/60/2008 (PDB ID: 4CPL) using PyMOL version 1.8.4.2 (Schrödinger).
Competition ELISAs. Microtitre 96-well plates (Immulon 4 HBX, Thermo Fisher Scientific) were coated with 2 µ g ml -1 (50 µ l per well) of rNA from B/ Florida/04/2006 diluted in coating solution (KPL). The plates were incubated at 4 °C overnight. The next day, plates were washed three times with PBS containing 0.1% Tween-20 (PBS-T) and then incubated for 1 h at 20 °C with 225 µ l per well of blocking solution (PBS-T with 3% goat serum (Life Technologies) and 0.5% milk powder). After the blocking solution was removed, the competing monoclonal antibodies were diluted in blocking solution at 20 µ g ml -1 and transferred to the plate. Blocking solution with no antibodies was used as a no-competition control. The final volume in each well after dilution was 100 µ l. After a 2 h incubation period at 20 °C, the plates were washed three times with PBS-T. Following the wash, the biotinylated target antibodies were diluted in 1:3 steps with a starting concentration of 30 μ g ml -1 in blocking solution and then incubated for 2 h at 20 °C. Subsequently, the plates were washed three times with PBS-T and then incubated with streptavidin conjugated to horseradish peroxidase (1:3,000, 50 µ l per well, Thermo Fisher Scientific). After 1 h at 20 °C, the plates were washed four times with PBS-T and then developed with SigmaFast o-phenylenediamine dichloride (OPD, 100 µ l per well, Sigma) for 10 min. The reaction was stopped with the addition of 3 M hydrochloric acid (50 µ l per well). The plates were immediately read using a Synergy H1 hybrid multimode microplate reader (BioTek) at an optical density of 490 nm.
Animals. All animal procedures were performed in accordance with the Icahn School of Medicine at Mount Sinai Institutional Animal Care and Use Committee (IACUC). Female mice (species, Mus musculus; strain, BALB/c) aged 4-6 weeks (The Jackson Laboratory) were used for all studies. Researchers performing animal experiments were not blinded. Mice were randomly assigned to infection and treatment groups without the use of a specific algorithm. A sample size of three mice per group was chosen for lung titre analyses and five mice per group for challenge studies according to the general practice in the influenza field. Sample sizes were not determined using power analyses. Mice in challenge experiments were scored dead on the day when an animal crossed the pre-defined humane weight loss endpoint or on the day when it was found dead (if this occurred before crossing the endpoint).
Evaluation of prophylactic and therapeutic efficacy in mice.
Prophylactic and therapeutic protection studies and quantification of viral lung titres in mice were performed as described in refs. 26, 27 .
PRNAs. PRNAs were performed according to the protocols described by Tan et al. 55 and Wohlbold et al. 27 , with some modifications. In duplicate, six fivefold dilutions of mAbs (highest concentration, 100 μ g ml -1 ; lowest concentration, 3.2 × 10 −1 μ g ml -1 ) were prepared in serum-free 1× MEM, and each dilution was incubated with 100 p.f.u. of virus for 1 h 30 min at RT, on a shaker. The inocula were then plaqued on MDCK cell monolayers in either 12-well (B/Victoria/2/87, B/Yamagata/16/88, B/Victoria/2/87 viruses) or 6-well (B/Malaysia/2506/04 virus) plates, similar to the protocol used to plaque lung titres (described earlier). After 3 days of incubation at 33 °C, the cells were fixed with 3.7% formaldehyde for at least 1 h at 4 °C and blocked with 3% milk in PBS for at least 1 h. For the primary antibody step, plates were then incubated with a cocktail of broadly reactive, anti-IBV HA mouse mAbs (1:5,000 dilution in PBS, 1% milk) for 1 h at RT, while shaking. Plates were washed with PBS and incubated with an anti-mouse secondary antibody conjugated to horseradish peroxidase (Sigma) for 30 min at 37 °C. Finally, plates were washed and stained with True-Blue (KPL) so plaques could be visualized and counted. The plaques were counted in each mAb dilution and the per cent inhibition for each mAb at each dilution was calculated based on a no-antibody control. An irrelevant murine IgG (8H9) was used as negative control. The data were analysed using Prism software (GraphPad). We also assessed the decrease in plaque size upon incubation with antibody. To analyse average plaque diameter, 10 plaques were randomly selected in each well using a technique described previously 27 .
Mouse ADCC reporter assays. Assessment of the ability of mAbs to trigger ADCC was performed using a commercial ADCC reporter kit (Promega) and according to the manufacturer's instructions. Briefly, MDCK cells were seeded into white, flatbottom, 96-well cell culture plates (Costar) at a density of 3.0 × 10 4 cells per well and incubated overnight at 37 °C and 5% CO 2 . The following day, the cells were infected with B/Yamagata/16/88, B/Malaysia/2506/04 or B/Florida/04/06 virus at an MOI of 3 and incubated at 33 °C, 5% CO 2 . Sixteen hours later, the cell medium was exchanged for threefold serial dilutions of antibody in assay buffer, starting at 30 μ g ml -1 . Effector cells were added and, after another 6 h of incubation (37 °C, 5% CO 2 ), Bio-Glo luminescence reagent and substrate (Promega) were added and luminescence was measured on a Synergy H1 microplate reader (BioTek). Data were analysed using Prism 6 software (GraphPad).
NA-Star assay. The NA-Star influenza neuraminidase inhibitor resistance detection kit (Applied Biosystems) was used to assess mAb (or Fab) inhibition of the ability of NA to cleave a small, soluble, chemiluminescent substrate (sodium (2-chloro-5-(4-methoxyspiro{1,2-dioxetane-3,2′ -(5-chloro)tricyclo[3.3.1.1 3, 7 ] decan}-4-yl-phenyl 5-acetamido-3,5-dideoxy-α -d-glycero-d-galacto-2nonulopyranoside)onate).
To measure antibody-mediated inhibition, mAb (or Fab) was diluted 1:3 in NA-Star assay buffer (starting concentration, 100 μ g ml -1 ; final volume per well, 25 μ l) in white, flat-bottom, 96-well cell culture plates. A 25 μ l volume of virus at the determined 3× EC 50 (half-maximum effective concentration) was added to each well, and the plates were shaken and incubated for 30 min at 37 °C. The remainder of the assay was performed in an identical manner to the method described above, beginning with the addition of NA-Star substrate. Data points were expressed as per cent inhibition of maximal NA enzymatic activity, which was Articles NAturE MIcroBIology determined by the activity of virus without the addition of antibody. Curves were plotted using Prism software (GraphPad).
Oseltamivir treatment studies. Oseltamivir phosphate (Fisher Scientific, US Pharmacopeia Reference Standard) was administered to mice via oral gavage twice daily (every 12 h) at a dose of 20 mg kg -1 (in a total volume of 100 μ l water for injection (Gibco)) for 6 days following treatment commencement. This dosing (40 mg kg -1 day -1 ) was based on recently published dosing regimens used in the BALB/c mouse model 56, 57 as well as the standard dosing recommended for therapeutic treatment in adult humans by ACIP 9 .
Statistical analysis. Statistical analysis was performed using Prism software (GraphPad). Lung virus titres were compared using a one-way analysis of variance (ANOVA) corrected for multiple comparisons. Differences in survival were analysed using a Mantel-Cox log rank test. Statistical significance is indicated, where tested, as follows: NS, P > 0.05; *P ≤ 0.05; **P ≤ 0.01; ***P ≤ 0.001; ****P ≤ 0.0001.
Data availability.
The data that support the findings of this study are contained in the manuscript or are available from the corresponding author upon request. The GEO reference for the RNA-Seq data pertaining to the viruses used in this paper is GSE96091 ( Supplementary Fig. 2 ). EM maps have been deposited in the EMDataBank under the following accession numbers: negative stain of influenza B virus recombinant neuraminidase bound to 1F2 Fab (EMD-8768), negative stain of influenza B virus recombinant neuraminidase bound to 4F11 Fab (EMD-8769) and negative stain of influenza B virus recombinant neuraminidase (EMD-8770).
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Experimental design 1. Sample size
Describe how sample size was determined.
No initial power analysis was done to select the number of mice used. An n of 3 mice/group was chosen for lung titer analysis and an n of 5 mice/ group for challenge studies based on available resources and according to the general practices in the influenza field.
Data exclusions
Describe any data exclusions. No data were excluded.
Replication
Describe whether the experimental findings were reliably reproduced. All experiments contained at least technical duplicates. Experimental findings were reliably reproduced. Specifically, the described mAbs are now being further developed as potential therapeutics and in vivo and in vitro results could be reproduced by independent operators.
Randomization
Describe how samples/organisms/participants were allocated into experimental groups.
Mice were randomly assigned to infection and treatment groups without a specific algorithm.
Blinding
Describe whether the investigators were blinded to group allocation during data collection and/or analysis.
The researchers were not blinded to group allocation.
Note: all studies involving animals and/or human research participants must disclose whether blinding and randomization were used.
Statistical parameters
For all figures and tables that use statistical methods, confirm that the following items are present in relevant figure legends (or the Methods section if additional space is needed).
n/a Confirmed
The exact sample size (n) for each experimental group/condition, given as a discrete number and unit of measurement (animals, litters, cultures, etc.)
A description of how samples were collected, noting whether measurements were taken from distinct samples or whether the same sample was measured repeatedly.
A statement indicating how many times each experiment was replicated
The statistical test(s) used and whether they are one-or two-sided (note: only common tests should be described solely by name; more complex techniques should be described in the Methods section)
A description of any assumptions or corrections, such as an adjustment for multiple comparisons
The test results (e.g. p values) given as exact values whenever possible and with confidence intervals noted A summary of the descriptive statistics, including central tendency (e.g. median, mean) and variation (e.g. standard deviation, interquartile range)
Clearly defined error bars
See the web collection on statistics for biologists for further resources and guidance.
